Food and drug administration approval of laboratory tests

Archives of Pathology and Laboratory Medicine

Volumn 137, Issue 1, 2013, Pages 13-18

  Allen, Timothy Craig ^a  

^a UNIVERSITY OF TEXAS HEALTH CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANAPLASTIC LYMPHOMA KINASE; CRIZOTINIB; PROTEIN TYROSINE KINASE; PYRAZOLE DERIVATIVE; PYRIDINE DERIVATIVE;

DIAGNOSTIC TEST APPROVAL; DRUG APPROVAL; FLUORESCENCE IN SITU HYBRIDIZATION; FOOD AND DRUG ADMINISTRATION; GENE FUSION; GENETICS; HISTORY; HUMAN; LUNG NON SMALL CELL CANCER; LUNG TUMOR; OFF LABEL DRUG USE; REVIEW; UNITED STATES;

CARCINOMA, NON-SMALL-CELL LUNG; DIAGNOSTIC TEST APPROVAL; DRUG APPROVAL; HISTORY, 20TH CENTURY; HISTORY, 21ST CENTURY; HUMANS; IN SITU HYBRIDIZATION, FLUORESCENCE; LUNG NEOPLASMS; OFF-LABEL USE; ONCOGENE FUSION; PYRAZOLES; PYRIDINES; RECEPTOR PROTEIN-TYROSINE KINASES; UNITED STATES; UNITED STATES FOOD AND DRUG ADMINISTRATION;

EID: 84872011249     PISSN: 00039985     EISSN: 15432165     Source Type: Journal    
DOI: 10.5858/arpa.2012-0077-ED     Document Type: Review

References (18)

1. Nelson R. Crizotinib is "major breakthrough for genomic medicine." Medscape Web site. http://www.medscape.com/viewarticle/748990. Published September 1, 2011. Accessed September 29, 2011.
2. Joly Y, Koutrikas G, Tassee AM, et al. Regulatory approval for new pharmacogenomic tests: A comparative overview. Food Drug Law J. 2011;66: 1-24.
3. Hall RF. Right question, wrong answer: A response to Professor Epstein and the "permititis" challenge. Minn Law Rev Headnotes. 2010;94:50-84.
4. Thalidomide-a second chance [program summary]? BBC Web site. http:// www.bbc.co.uk/science/horizon/2004/thalidomide.shtml. Accessed 12/3/11.
5. Epstein RA. Against permititis: Why voluntary organizations should regulate the use of cancer drugs. Minn Law Rev. 2009;94:1-42.
6. Klasmeier C, Redish MH. Off-label prescription advertising, the FDA, and the First Amendment: A study in the values of commercial speech protection. Am J Law Med. 2011;37(2-3):315-357.
7. Park Y, Jones DP, Ziegler TR, et al. Metabolic effects of albumin therapy in acute lung injury measured by proton nuclear magnetic resonance spectroscopy of plasma: A pilot study. Crit Care Med. 2011;39(10):2308-2313.
8. Somberg JC. The Food and Drug Administration's paternalism. Am J Ther. 2010;17(6):533-534.
9. Pipes S. It's time to blow up the FDA's drug review process. Forbes. November 7, 2011. http://www.forbes.com/sites/sallypipes/2011/11/07/its-timeto- blow-up-the-fdas-drug-review-process/. Accessed January 5, 2012.
10. Hinman LM, Carl KM, Spear BB, et al. Development and regulatory strategies for drug and diagnostic co-development. Pharmacogenomics. 2010; 11(12):1669-1675.
11. Ginocchio CC. Strengths and weaknesses of FDA-approved/cleared diagnostic devices for the molecular detection of respiratory pathogens. Clin Infect Dis. 2011;52(suppl 4):S312-S325.
12. Vladutiu GD. SIMD commentary on FDA oversight of laboratorydeveloped testing. Mol Genet Metab. 2011;102(1):1-3.
13. Vance GH. College of American Pathologists proposal for the oversight of laboratory-developed tests. Arch Pathol Lab Med. 2011;135(11):1432-1435.
14. College of American Pathologists. Comments to the Food and Drug Administration on the draft guidance "In Vitro Companion Diagnostic Devices." http://www.cap.org/apps/docs/advocacy/comments/comments-fda- draft-guidance. pdf. Published October 12, 2011. Accessed Accessed January 5, 2012.
15. Paxton A. Bumpy landing for precision medicine. CAP Today. 2011,25:1, 50, 52, 54, 56.
16. Hoffman J. AMP comments on FDA companion diagnostic devices draft guidance. ADVANCE Discourse: Lab. http://community.advanceweb.com/blogs/ al-2/archive/2011/12/09/amp-comments-on-fda-companion-diagnostic-devicesdraft- guidance.aspx. Published December 9, 2011. Accessed November 5, 2011.
17. Association for Molecular Pathology. AMP comments regarding FDA draft guidance for "in vitro companion diagnostic devices." http://www.amp. org/publications-resources/position-statements-letters/documents/AMPResponse CompanionDx-Final.pdf. Accessed January 5, 2012.
18. What pathologists and the CAP can do to assist with PMA process. Digital Pathology Blog Web site. http://www.tissuepathology.com/weblog/2011/12/ what-pathologists-and-the-cap-can-do-to-assist-with-pma-process.html. Accessed January 5, 2012.